Genetics of immunoglobulin a nephropathy

Annals of the Academy of Medicine Singapore

Volumn 29, Issue 3, 2000, Pages 364-369

  Tanaka, Ryojiro ^a   Iijima, K ^c   Nakamura, H ^c   Yoshikawa, N ^b  

^a HIMEJI RED CROSS HOSPITAL   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NONE

Author keywords

Genetic factor; IgA immune system; Platelet activating factor acetylhydrolase; Renin angiotensin system

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; NEUROPEPTIDE Y; PHOSPHOLIPASE A; THROMBOCYTE ACTIVATING FACTOR;

GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; PHENOTYPE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS, IGA; HUMANS; NEUROPEPTIDE Y; PHENOTYPE; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 0034185257     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Yoshikawa N, Ito H, Yoshiara S, Nakahara C, Yoshiya K, Hasegawa O, et al. Clinical course of immunoglobulin A nephropathy in children. J Pediatr 1987; 110:555-60.
2. Yoshikawa N, Iijima K, Maehara K, Yoshiara S, Yoshiya K, Matsuo T, et al. Mesangial changes in IgA nephropathy in children. Kidney Int 1987; 32:585-9.
3. Emancipator S N, Gallo G R, Lamm M E. IgA nephropathy: Perspective on pathogenesis and classification. Clin Nephrol 1985; 24:161-79.
4. Yoshikawa N, Iijima K, Ito H. IgA nephropathy. Nephron 1999; 83: 1-12.
5. Rambausek M H, Waldherr R, Ritz E. Immunogenetic findings in glomerulonephritis. Kidney Int 1993; 43:S3-8.
6. Schmidt S, Ritz E. Genetic factors in IgA nephropathy. Ann Med Intern 1999; 150:86-90.
7. Katajima T, Murakami M, Sakai O. Clinicopathological features in the Japanese patients with IgA nephropathy. Jpn J Med 1983; 22: 219-22.
8. Berger J, Yaneva H, Crosnier J. La glomérulonéphrite à depôts mesangiaux d' IgA: Une cause fréquente d' insuffisance rénale terminale. Nouv press Méd 1980; 9:219-21.
9. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 64:709-27.
10. Clarkson A R, Seymour A E, Thompson A J, Haynes W D G, Chan Y L, Jackson B. IgA nephropathy: a syndrome of uniform morphology, diverse clinical features and uncertain prognosis. Clin Nephrol 1977; 8:459-71.
11. Hood SA,Velosa JA,Holley KE,DonadioJrJV.IgA-IgG nephropathy: predictive indices of progressive disease. Clin Nephrol 1981; 16:55-62.
12. Sissons J G P, Woodrow D F, Crutis J R, Evans D J, Gower P E, Sloper J C, et al. Isolated glomerulonephritis with mesangial IgA deposits. BMJ 1975; 3:611-4.
13. Katz A, Walker J F, Landy P J. IgA nephritis with nephrotic range proteinuria. Clin Nephrol 1983; 20:67-71.
14. Jennette J C, Wall S D, Wilkman A S. Low incidence of IgA nephropathy in blacks. Kidney Int 1985; 28:944-50.
15. Galla J H, Kohaut E C, Alexander R, Mestecky J. Racial difference in the prevalence of IgA-associated nephropathies. Lancet 1984; ii:522.
16. Smith S M, Tung K S K. Incidence of IgA-related nephritides in American Indians in New Mexico. Hum Pathol 1985; 16:181-4.
17. Yokoska H, Nagase M, Maeda T, Koide K. Mesangial IgA glomerulonephritis: Clinicopathological study of 85 cases. Contrib Nephrol 1978; 9:101-10.
18. Julian B A, Quiggins P A, Thompson J S, Woodford S Y, Gleason K, Wyatt R J. Familial IgA nephropathy. Evidence for an inherited mechanism of disease. N Engl J Med 1985; 312:202-8.
19. Wyatt R J, Rivas M L, Julian B A, Quiggins P A, Woodford S Y, McMorrow R G, et al. Regionalization in hereditary IgA nephropathy. Am J Hum Genet 1987; 41:36-50.
20. Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, et al. Familial clustering of IgA nephropathy: Further evidence in an Italian population. Am J Kidney Dis 1999; 33:857-65.
21. Berthoux F C, Gagne A, Sabatier J C, Ducret F, Le Petit J C, Marcellin M, et al. HLA-Bw35 and mesangial IgA glomerulonephritis. N Engl J Med 1978; 298:1034-5.
22. Richman A V, Mahoney J J, Fuller T J. Higher prevalence of HLA-B12 in patients with IgA nephropathy. Ann Intern Med 1979; 90:201.
23. Komori K, Nose Y, Inouye H, Tsuji K, Nomoto Y, Tomino Y, et al. Immunogenetical study in patients with chronic glomerulonephritis. Tokai J Exp Clin Med 1983; 8:135-48.
24. Hiki Y, Kobayashi Y, Tateno S, Sada M, Kashiwagi J N. Strong association of HLA-DR4 with benign nephropathy. Nephron 1982; 32:222-6.
25. Feehally J, Dyer P A, Davidson J A, Harris R, Mallick N P. Immunogenetics of IgA nephropathy: Experience in an UK centre. Dis Markers 1984; 2:493-500.
26. Moore R H, Hitman G A, Lucas E Y, Richards N T, Venning M C, Papiha S, et al. HLA DQ region gene polymorphism associated with primary IgA nephropathy. Kidney Int 1990; 37:991-5.
27. Li P K T, Burns A P, So A K L, Pusey C D, Feehally J, Rees A J. The DQw7 allele at the HLA-DQB locus is associated with susceptibility to IgA nephropathy in Caucasians. Kidney Int 1991; 39:961-5.
28. Li P K T, Poon A S Y, Lai K N. Molecular genetics of MHC class II alleles in Chinese patients with IgA nephropathy. Kidney Int 1994; 46:185-90.
29. Abe J, Kohsaka T, Tanaka M, Kobayashi N. Genetic study on HLA class II and class III region in the disease associated IgA nephropathy. Nephron 1993; 65:17-22.
30. McLean R H, Wyatt R J, Julian B A. Complement phenotypes in glomerulonephritis: Increased frequency of homozygous null C4 phenotypes in IgA nephropathy and Henoch-Schönlein purpura. Kidney Int 1984; 26:855-60.
31. Rambausek M, van den Wall Bake A W L, Schumacher-Ach R, Spitzenberg R, Rother U, van Es L A, et al. Genetic polymorphism of C3 and Bf in IgA nephropathy. Nephrol Dial Transplant 1987; 2:208-11.
32. Schena F P, Scivittaro V, Ranieri E, Sinico R, Benuzzi S, Di Cillo M, et al. Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy. Clin Exp Immunol 1993; 92:139-44.
33. Scivittaro V, Ranieri E, Di Cillo M, Aventaggiato L, Emancipator S N, Schena F P. In vitro immunoglobulin production in relatives of patients with IgA nephropathy. Clin Nephrol 1994; 42:1-8.
34. Demaine A G, Rambausek M, Knight J F, Williams D G, Welsh K I, Ritz E. Relation of mesangial IgA glomerulonephritis to polymorphism of immunoglobulin heavy chain switch region. J Clin Invest 1988; 81: 611-4.
35. Shimomura M, Yoshikawa N, lijima K, Nakamura H, Miyazaki M, Sakai H. Polymorphism of immunoglobulin heavy chain switch region gene in children with severe IgA nephropathy. Clin Nephrol 1995; 43:211-5.
36. Yano N, Asakura K, Endoh M, Abe Y, Nomoto Y, Sakai H, et al. Polymorphism in the I1 germ-line transcript regulatory region and IgA productivity in patients with IgA nephropathy. J Immunol 1998; 160:4936-42.
37. Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, et al. Protective role of IgAl glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998; 9:2048-54.
38. Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J. Galactose-deficient IgAl in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997; 52:509-16.
39. Greer M R, Barratt J, Harper S J, Allen A C, Feehally J. The nucleotide sequence of the IgAl hinge region in IgA nephropathy. Nephrol Dial Transplant 1998; 13:1980-3.
40. Allen A C, Topham P S, Harper S J, Feehally J. Leucocyte βl,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant 1997; 12:701-6.
41. Amado M, Almeida R, Carneiro F, Levery S B, Holmes E H, Nomoto M, et al. A family of human β3-galactosyltransferases. J Biol Chem 1998; 273:12770-8.
42. Zhou D, Berger E G, Hennet T. Molecular cloning of a human UDP-galactose: GlcNAcbete 1, 3 GalNAc betal, 3 galactosyltransferase gene encoding an O-linked core-elongation enzyme. Eur J Biochem 1999; 263:571-6.
43. Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, et al. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993; 21:593-602.
44. Cattran D C, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting-enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23:247-54.
45. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-6.
46. Harden P N, Geddes C, Rowe P A, Mcllroy J H, Boulton-Jones M, Rodger R S C, et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345:1540-2.
47. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, et al. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96:2162-9.
48. Hunley T E, Julian B A, Phillips III J A, Summar M L, Yoshida H, Horn R G, et al. Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996; 49:571-7.
49. Tanaka R, Iijima K, Murakami R, Koide M, Nakamura H, Yoshikawa N. ACE gene polymorphism in childhood IgA nephropathy: association with clinicopathological findings. Am J Kidney Dis 1998; 31:774-9.
50. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330:1629-33.
51. Pei Y, Scholey J, Thai K, Suzuki M, Cattran D. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 1997; 100:814-20.
52. Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24 63-9.
53. Stafforini D M, Satoh K, Atkinson D L, Tjoelker L W, Eberhardt C, Yoshida H, et al. Platelet-activating factor acetylhydrolase deficiency: A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97:2784-91.
54. Tanaka R, Iijima K, Xu H, Inoue Y, Murakami R, Shirakawa T, et al. Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy. Am J Kidney Dis 1999; 34: 289-95.
55. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al for the Japanese Pediatric IgA Nephropathy Treatment Study Group. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 1999; 10:101-9.
56. Herzog H, Baumgartner M, Vivero C, Selbie L A, Auer B, Shine J. Genomic organization, localization and allelic differences in the gene for the human neuropeptide YY1 receptor. J Biol Chem 1993; 268: 6703-7.
57. Herzog H, Selbie L A, Zee R Y L, Morris B J, Shine J. Neuropeptide-YY1 receptor gene polymorphism: cross-sectional analyses in essential hypertension and obesity. Biochem Biophys Res Commun 1993; 196: 902-6.
58. Ito H, Morita T, Suehiro T, Tahara K, Ikeda Y, Nakauchi Y, et al. Neuropeptide Y Y1 receptor polymorphism as a prognostic predictor in Japanese patients with IgA nephropathy. Clin Nephrol 1999; 51:272-9.
59. Deenitchina S S, Shinozaki M, Hirano T, Ando T, Hirakata H, Kiyohara Y, et al. Association of a T-cell receptor constant alpha chain gene polymorphism with progression of IgA nephropathy in Japanese patients. Am J Kidney Dis 1999; 34:279-88.
60. Li P K T, Poon P, Phil M, Poon A S Y, Szeto C C, Yu A W Y, et al. Association of IgA nephropathy with T-cell receptor constant alpha chain gene polymorphism. Am J Kidney Dis 1997; 30:260-4.